A Possible Breakthrough?

[ALTACITIES.COM] ... ON THE RESEARCH PATH FOR NHL VACCINE: Accentia anticipates reporting a significant milestone in April, as the Company's majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), is preparing to report the interim unblinded results of its pivotal Phase 3 study for the anti-cancer vaccine, BiovaxID(TM). These results, if positive, are expected to poise BiovaxID to become the first personalized anti-cancer vaccine to ever be granted approval for the treatment of non-Hodgkin's lymphoma.

..........

@ltaLINK to This SOURCE